BR112021016605A2 - Preparações de membrana bacteriana - Google Patents

Preparações de membrana bacteriana

Info

Publication number
BR112021016605A2
BR112021016605A2 BR112021016605A BR112021016605A BR112021016605A2 BR 112021016605 A2 BR112021016605 A2 BR 112021016605A2 BR 112021016605 A BR112021016605 A BR 112021016605A BR 112021016605 A BR112021016605 A BR 112021016605A BR 112021016605 A2 BR112021016605 A2 BR 112021016605A2
Authority
BR
Brazil
Prior art keywords
membrane preparations
bacterial membrane
bacterial
preparations
mps
Prior art date
Application number
BR112021016605A
Other languages
English (en)
Inventor
Baundauna Bose
Brian Goodman
B Troy Erin
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of BR112021016605A2 publication Critical patent/BR112021016605A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631Chimeric Antigen Receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464401Neoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50Colon
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

preparações de membrana bacteriana. a presente invenção refere-se a métodos e composições relacionadas às preparações de membrana (mps) úteis como agentes terapêuticos.
BR112021016605A 2019-02-22 2020-02-21 Preparações de membrana bacteriana BR112021016605A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962809292P 2019-02-22 2019-02-22
PCT/US2020/019154 WO2020172492A2 (en) 2019-02-22 2020-02-21 Bacterial membrane preparations

Publications (1)

Publication Number Publication Date
BR112021016605A2 true BR112021016605A2 (pt) 2022-01-18

Family

ID=70005742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016605A BR112021016605A2 (pt) 2019-02-22 2020-02-21 Preparações de membrana bacteriana

Country Status (13)

Country Link
US (1) US20220118030A1 (pt)
EP (1) EP3927356A2 (pt)
JP (1) JP2022520999A (pt)
KR (1) KR20210133986A (pt)
CN (1) CN113727722A (pt)
AR (1) AR118171A1 (pt)
AU (1) AU2020225473A1 (pt)
BR (1) BR112021016605A2 (pt)
CA (1) CA3130776A1 (pt)
CO (1) CO2021012176A2 (pt)
MX (1) MX2021010160A (pt)
TW (1) TW202045192A (pt)
WO (1) WO2020172492A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518781B (zh) * 2019-07-31 2022-02-15 江南大学 一种谷氨酰胺转氨酶复合酶及其在人造肉加工中的应用
WO2021067626A2 (en) 2019-10-01 2021-04-08 Intima Bioscience, Inc. Genetic engineering of fungi to modulate tryptamine expression
US20240066074A1 (en) * 2020-09-11 2024-02-29 California Institute Of Technology Probiotic treatments for parkinson's disease
TW202233214A (zh) * 2020-11-06 2022-09-01 美商艾弗洛生物科技股份有限公司 使用小韋榮氏球菌細菌誘導免疫效應
TW202237155A (zh) * 2020-12-14 2022-10-01 美商艾弗洛生物科技股份有限公司 細胞外囊泡製劑
EP4284400A1 (en) * 2021-01-26 2023-12-06 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
CN112899188A (zh) * 2021-01-29 2021-06-04 西南大学 一种促进作物根系发育的微生物菌剂及其制备与应用
TW202302125A (zh) * 2021-03-05 2023-01-16 美商艾弗洛生物科技股份有限公司 固體劑型
KR102582570B1 (ko) * 2021-03-19 2023-09-22 한국생명공학연구원 유박테리움 칼란데리, 이의 배양액 또는 이의 배양액 추출물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물
CN115305211A (zh) * 2021-05-07 2022-11-08 葡萄王生技股份有限公司 益生菌胞外泌体及其用途
EP4363553A1 (en) * 2021-06-30 2024-05-08 Kiverdi, Inc. Reduction of endotoxins in bacterial protein preparations
EP4376880A1 (en) * 2021-07-28 2024-06-05 The Texas A&M University System Vaccine compositions comprising brucella strains and methods thereof
KR20230057980A (ko) * 2021-10-20 2023-05-02 주식회사 고바이오랩 항암 활성을 갖는 신규 박테리아 균주 및 이를 이용한 암의 완화, 예방 또는 치료용 조성물
CN114085875B (zh) * 2021-11-10 2023-04-25 四川大学 一种胞外多糖、制备方法及其应用
CN114410503B (zh) * 2021-12-08 2023-10-03 中南大学 一种锰氧化菌及其筛选方法和应用
WO2023114295A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
TWI819483B (zh) * 2022-01-28 2023-10-21 加捷生醫股份有限公司 乳酸菌組成物及其用於製備抑制抗藥性腸桿菌之口服組成物的用途
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用
WO2023195008A1 (en) * 2022-04-05 2023-10-12 Mybiotics Pharma Ltd. Bacterial compositions and methods for growing bacteria on particles
WO2023215869A2 (en) * 2022-05-06 2023-11-09 Biological Mimetics, Inc. Inactivated staphylococcus compositions and methods of making and using the same
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
WO2023239728A1 (en) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
KR102509869B1 (ko) * 2022-07-14 2023-03-14 주식회사 엔테로바이옴 아커만시아를 포함하는 탈모 예방 또는 치료용 약학적 조성물
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院(北京大学第三临床医学院) 一种用于调节杀伤性t细胞活性的方法、药物及其应用
KR102555748B1 (ko) * 2023-03-23 2023-07-17 주식회사 그린스토어 항균, 항진균, 항염 활성 및 치아 우식 억제 활성을 갖는 신규한 스트렙토코커스 살리바리우스 균주 kccm13161p 및 이를 포함하는 구강용 조성물
CN116212091B (zh) * 2023-05-09 2023-08-01 天津包钢稀土研究院有限责任公司 一种复合抗菌剂、人体友好型医用抗菌敷料及其制备方法
CN116794313B (zh) * 2023-08-18 2023-11-03 江西赛基生物技术有限公司 基于流式细胞仪同时检测三项肿瘤标志物的试剂盒及方法
CN117264850B (zh) * 2023-11-09 2024-05-14 潍坊君薇生物科技有限责任公司 一种具有辅助治疗阴道炎和增强免疫力功能的戊糖片球菌sw006及其应用
CN117264854B (zh) * 2023-11-17 2024-01-26 云南农业大学 一种植物乳杆菌及其应用
CN117402794B (zh) * 2023-12-12 2024-02-27 四川厌氧生物科技有限责任公司 一种加氏乳杆菌及其应用
CN117603884B (zh) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2523154A1 (fr) * 1982-03-09 1983-09-16 Fabre Sa Pierre Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant
DE19703437A1 (de) * 1997-01-30 1998-08-06 Luitpold Pharma Gmbh Gemische äußerer Membranen und/oder Zellwände von Bakterien zur oralen Immunisierung gegen Schleimhautinfektionen
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
FR2822071B1 (fr) * 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2670669T3 (es) * 2011-07-07 2018-05-31 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Proceso para la producción sin detergente de vesículas de membrana externa de una bacteria gram-negativa
US9764027B2 (en) * 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
MX2020002659A (es) * 2017-09-08 2020-09-09 Evelo Biosciences Inc Vesiculas extracelulares bacterianas.
WO2020006216A1 (en) * 2018-06-27 2020-01-02 Evelo Biosciences, Inc. Compositions and methods of treating cancer using neisseria bacteria

Also Published As

Publication number Publication date
EP3927356A2 (en) 2021-12-29
AR118171A1 (es) 2021-09-22
KR20210133986A (ko) 2021-11-08
JP2022520999A (ja) 2022-04-04
WO2020172492A3 (en) 2020-10-08
MX2021010160A (es) 2021-09-14
AU2020225473A1 (en) 2021-09-30
CA3130776A1 (en) 2020-08-27
US20220118030A1 (en) 2022-04-21
CO2021012176A2 (es) 2021-09-30
WO2020172492A2 (en) 2020-08-27
CN113727722A (zh) 2021-11-30
TW202045192A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
BR112021016605A2 (pt) Preparações de membrana bacteriana
BR112021024830A2 (pt) Vesículas extracelulares microbianas processadas
CO2020004233A2 (es) Vesículas extracelulares bacterianas
MX2020002660A (es) Vesiculas extracelulares de prevotella.
MX2020008542A (es) Composiciones y métodos para el suministro de proteínas membranales.
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2021008592A (es) Composiciones de trem y usos de las mismas.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
CY1125211T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2022011694A (es) Metodos para hacer agentes de contraste por ultrasonido.
BR112019005329A2 (pt) composições de oligossacarídeos de leite humano purificadas
WO2019178487A3 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
BR112018012388A2 (pt) imunoglobulinas conjugadas de lisina terminal-c
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
CL2021002108A1 (es) Desinfectante endoscopico mejorado
BR112022001913A2 (pt) Métodos e composições para cultivar bactérias dependentes de hemoglobina
CO2023000510A2 (es) Mezclas fungicidas
BR112021011124A2 (pt) Anelossomos e métodos de uso
CL2019003167A1 (es) Proteínas de unión al antígeno anti-jagged1.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
PH12020551618A1 (en) Erenumab compositions and uses thereof
BR112021023169A2 (pt) Métodos e composições para fermentação bacteriana anaeróbica
MX2021005910A (es) Formulacion de proteina de alta concentracion.
CL2019001469S1 (es) Cepillo de dientes.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2762 DE 12-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.